Search Our Scientific Publications & Authors

Leuk Res 2021 Feb 15;103:106537. Epub 2021 Feb 15.

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China; Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guandong, 510060, China. Electronic address:

Introduction: Patients with hematologic malignancies are prone to developing thromboembolism. The incidence, risk factors and clinical features for developing venous thromboembolism (VTE) are not well-elucidated in patients with T-cell lymphoma.

Materials And Methods: The present study retrospectively analyzed 668 patients with VTE, including pulmonary embolism (PE) and deep vein thrombosis (DVT), who were admitted to Tianjin Medical University Cancer Institute and Hospital and Sun Yat-sen University Cancer Center from January 2006 to December 2018. Read More

Adv Hematol 2021 29;2021:8870015. Epub 2021 Jan 29.

Antithrombotic Therapy Team, NYU Langone Health-Department of Medicine, Perlmutter Cancer Center 38th Street, New York, NY 10016, USA.

Introduction: Warfarin remains the preferred oral anticoagulant for the treatment of venous thromboembolism (VTE) in patients with advanced chronic kidney disease (CKD). Although the direct oral anticoagulants (DOACs) have become preferred for treatment of VTE in the general population, patients with advanced CKD were excluded from the landmark trials. Postmarketing, safety data have demonstrated oral factor Xa inhibitors (OFXais) such as apixaban and rivaroxaban to be alternatives to warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Read More

Pediatr Blood Cancer 2021 Feb 24:e28957. Epub 2021 Feb 24.

Children's Hospital Los Angeles, Los Angeles, California, USA.

Background: Venous thromboembolism (VTE) is a known complication among pediatric and adult cancer patients. Adolescent and young adult oncology (AYAO) patients have unique biological and physiological characteristics that make them distinct from other populations. Our objective was to study the VTE incidence, risk factors, and outcomes, which have been understudied in this population. Read More

J Pediatr Gastroenterol Nutr 2021 Jan 14. Epub 2021 Jan 14.

*Department of Pediatrics, Weill Cornell Medicine, New York, NY †Department of Population Health Sciences, Weill Cornell Medicine, New York, NY ‡MSCH Administration, New York-Presbyterian Morgan Stanley Children's Hospital, New York, NY.

Venous thromboembolism (VTE) is a known complication in children with inflammatory bowel disease (IBD). Despite awareness of the increased thrombosis risk in this population, prophylaxis is not standardly used and there is limited published guidance for thrombosis prevention. To better appreciate the impact of thrombosis in this population, we compared children with IBD who did or did not have a VTE, using the Pediatric Health Information System inpatient database from 2009-2017. Read More

J Oncol Pharm Pract 2021 Feb 20:1078155221995885. Epub 2021 Feb 20.

Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Introduction: Immunomodulatory drugs used to treat multiple myeloma carry an increased risk of venous thromboembolic (VTE) disease. Previously published guidelines outline consensus opinion on how to mitigate this risk.

Methods: We collected baseline data to analyze how these strategies are utilized at our single institution and sought to improve the rates of anticoagulation for high-risk patients. Read More